Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

Got To Article
FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced that the U.S. Food and Drug Administration (FDA
0 comments

VR edtech company connected to ASU raises $20M in series A funds

Got To Article
Dreamscape Learn was developed through a two-year partnership between ASU and VR company Dreamscape Immersive. An immersive learning educational technology company developed in collaboration with Arizona State University has raised $20 million in series A funding as it continues building its virtual reality-enabled coursework and platform and putting them to work in classrooms.
0 comments

Michelle Vartan

Got To Article
Michelle Vartan is a mission-driven journalist and on-camera correspondent covering health and lifestyle topics for digital, TV and print publications. She is the Editor in Chief of DailyOM Journal and has previously produced or written for the LA Times,
0 comments